2Carpelan-Holmstrom M, Nordling S, Pukkala E, et al. Does anyone survive pancreatic ductal adenocarcinoma? A nationwide study re-evaluating the data of the Finnish Cancer Registry [ J ]. Gut,2005,54 ( 3 ) : 385 - 387.
4Neoptolemos JP, Stocken DD, Friess H, et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer[J]. N Engl J Med, 2004, 350(12) :1200 - 1210.
5Neuhaus P, Oettle H, Post S, et al. A randomized, prospective,multicenter, phase Ⅲ trial of adjuvant chemotherapy with gcmcitabine vs observation in patients with resected pancreatlc cancer[J]. Pmc Am Soc Clin Oncol, 2005, 24; Abstract 4013.
6Regine WF, Winter KW, Abrams R, et al. RTOG 9704 a phase Ⅲ study d adjuvant pre and post chemoradiation ( CRT ) 5-FU vs. gemcitabine (G) for resected pancreatic adenocareinoma[ J].Proc Am Soc Clin Oncol, 2006, 24 : Abstract 4007.
7Jacobs AD, Burris HA, Rivkin S, et al. A randomized phase Ⅲ study of rubitecan (ORA) vs. best choice (BC) in 409 patients with refractory pancreatic cancer report from a North-American multi-center study[J]. Pmc Am Soc Clin Oncol, 2004, 23:Ab-stract 4013.
8Stathopouios GP, Syrlgos K, Aravantinos G, et al. A multicenterphase Ⅲ trial comparing irinotecan-gemeitabine (IG) with gemcitabine (G) monotherapy as first-line treatment in patients with locally advanced or metastatic pancreatic cancer[ J ]. Br J Cancrer, 2006,95 (5) :587 - 592.
10Louvet C, Labianca R, Hammel P, et al. Gemox (gemcitabine +oxaliplatin) versus Gem (gemcitabine) in non resectable pancreatic adenocarcinoma: Final results of the GERCOR/GISCADIntergroup Phase Ⅲ trial[J]. Proc Am Soc Clln Oncol, 2004, 23; Abstraet 4008.
3[1]Burris HA 3rd, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer:a randomized trial [J]. J Clin Oncol, 1997, 15:2403-2413.
4[2]Berlin JD, Catalano P,Thomas JP, et al. Phase Ⅲ study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma. Eastern Cooperative Oncology Group Trial E2297 [J]. J Clin Oncol,2002, 20: 3270-3275.
5[3]Evans JD, Stark A, Johnson CD, et al. A phase Ⅱ trial of marimastat in advanced pancreatic cancer [J]. Br J Cancer,2001,85:1865-1870.
6[4]Zujewski J,Horak ID, Bol C J, et al. Phase Ⅰ and pharmacokinetic study of farnesyl protein transferase inhibitor R115777 in advanced cancer [J]. J Clin Oncol, 2000, 18:927-941.
7[5]Adjei AA, Erlichman C, Davis JN, et al. A phase Ⅰ trial of the farnesyl transferase inhibitor SCH66336: evidence for biological and clinical activity [ J ]. Cancer Res, 2000,60:1871-1877.
8[6]Patnaik A, Eckhardt S, Izbicka E, et al. A phase Ⅰ and pharmacokinetic (PK) study of the farnesyltransferase inhibitor,R115777 in combination with gemcitabine (Gem) [C]. Proc Annu Meet Am Soc Clin Oncol, 2000, 5A. Abstract.
9[7]Abbruzzese JL, Rosenberg A, Xiong Q, et al. Phase Ⅱ study of anti-epidermal growth factor receptor(EGFR) antibody cetuximab (IMC-C225) in combination with gemcitabine in patients with advanced pancreatic cancer[C]. Proc Annu Meet Am Soc Clin Oncol, 2001,518. Abstract.
10[8]Hidalgo M, Siu LL, Nemunaitis J, et al. Phase Ⅰ and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies [J]. J Clin Oncol, 2001, 19:3267-3279.
2Ciardiello F, Bianco R, Caputo R, et al. Antitumor activity of ZD6474, a vascular endothelial growth factor receptor tymsine kinase inhibitor,in human cancer ceils with acquired resistance to antiepidermal growth factor receptor therapy [ J ]. Clin Cancer Res,2004,10(2) :784 -793.
3Takahashi H, Sawai H, Funahashi H, et al. Antiproteases in preventing the invasive potential of pancreatic cancer cells[J]. JOP, 2007,8 ( 4 Suppl ) : 501 - 508.
4Evans JD, Stark A, Johnson CD, et al. A phase Ⅱ trial of marimastat in advanced pancreatic cancer[ J]. Br J Cancer, 2001, 85(12) :1865 - 1870.
5Bramhall SR, Rosemurgy A, Brown PD, et al. Marimastat as first -line therapy for patients with unresectable pancreatic cancer: a randomized trial[ J ]. J CIin Oncol,2001,19 ( 15 ) :3447 - 3455.
6Bramhall SR, Schulz J, Nemunaitis J, et al. A double - blind placebo - controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy irt patients with advanced pancreatic cancer[J]. BrJ Cancer,2002, 87(2) :161 - 167.
7Bloomston M, Zervos EE, Rosemurgy AS, et al. Matrix metalloproteinases and their role in pancreatic cancer: a review of preclinical studies and clinical trials [ J ]. Ann Surg Oncol,2002,9 ( 7 ) : 668 - 674.
8Giovannetti E, Mey V, Nannizzi S, et al. Pharmaeogenetics of anticancer drug sensitivity in pancreatic cancer [ J ]. Mol Cancer Ther, 2006,5(6) :1387 - 1395.
